Guggenheim Upgrades Guardant Health to Buy, Announces $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Subbu Nambi has upgraded Guardant Health (NASDAQ:GH) from Neutral to Buy and set a price target of $36.
June 28, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Subbu Nambi has upgraded Guardant Health from Neutral to Buy and set a price target of $36.
The upgrade from Neutral to Buy and the announcement of a $36 price target by a reputable analyst at Guggenheim is likely to positively impact Guardant Health's stock price in the short term. Such upgrades often lead to increased investor confidence and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100